FDA fast tracks Pfizer’s C. diff vaccine

The U.S. Food and Drug Administration has granted Fast Track designation to Pfizer’s investigational Clostridium difficile vaccine, which is in Phase 2 clinical development.

Advertisement

The FDA’s Fast Track is designed to facilitate the development and expedite the review of new vaccines intended to treat or prevent serious conditions and address unmet medical need, according to Pfizer.

Pfizer’s vaccine is designed to prevent diseases associated with C. diff, which can include life-threatening diarrhea and pseudomembranous colitis. Currently, there is no C. diff vaccine, even though C. diff- related diseases lead to about 14,000 deaths in the United States each year.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.